Pleskow W W, Stevenson D D, Mathison D A, Simon R A, Schatz M, Zeiger R S
J Allergy Clin Immunol. 1982 Jan;69(1 Pt 1):11-9. doi: 10.1016/0091-6749(82)90081-1.
Thirty aspirin-sensitive asthmatic patients underwent incremental, oral aspirin challenge until a "positive reaction" (delta FEV1 greater than or equal to 25%) occurred. After this reaction, aspirin was readministered in an attempt to achieve "desensitization." This was defined as the ability of the patient to ingest 650 mg of aspirin without experiencing upper or lower respiratory-tract symptoms or a decrease in lung function. To determine the "refractory period" following aspirin desensitization, patients were rechallenged after various intervals (days) without aspirin until a positive reaction recurred. All 30 aspirin-sensitive asthmatic patients were successfully desensitized to aspirin. Individual patient refractory periods ranged from less than 2 days to greater than 5 days, with most patients gradually returning to sensitivity between 2 to 4 days. Cross-densensitization with indomethacin and other nonsteroidal anti-inflammatory drugs was also demonstrated. These studies show that aspirin desensitization can be safely achieved in aspirin-sensitive asthmatic patients; however, this desensitization will gradually disappear over several days when additional aspirin is withheld.
30名阿司匹林敏感型哮喘患者接受递增剂量的口服阿司匹林激发试验，直至出现“阳性反应”（第一秒用力呼气容积（FEV1）下降大于或等于25%）。出现此反应后，再次给予阿司匹林以试图实现“脱敏”。脱敏定义为患者能够摄入650毫克阿司匹林而不出现上、下呼吸道症状或肺功能下降。为了确定阿司匹林脱敏后的“不应期”，在不同间隔时间（天数）不给患者服用阿司匹林后再次进行激发试验，直至再次出现阳性反应。所有30名阿司匹林敏感型哮喘患者均成功实现了对阿司匹林的脱敏。个体患者的不应期从不到2天到超过5天不等，大多数患者在2至4天之间逐渐恢复敏感性。还证实了对吲哚美辛和其他非甾体抗炎药的交叉脱敏作用。这些研究表明，阿司匹林敏感型哮喘患者能够安全地实现阿司匹林脱敏；然而，当停用额外的阿司匹林时，这种脱敏作用会在几天内逐渐消失。
